299 related articles for article (PubMed ID: 31379316)
1. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
Koo R; Lo J; Bock MJ
Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
3. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
4. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
5. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
6. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
[TBL] [Abstract][Full Text] [Related]
7. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
[TBL] [Abstract][Full Text] [Related]
8. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
Thurber KM; Williams BM; Bates RE; Frantz RP
Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
[TBL] [Abstract][Full Text] [Related]
9. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
El-Kersh K; Smith JS
Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
[No Abstract] [Full Text] [Related]
10. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
[TBL] [Abstract][Full Text] [Related]
11. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
12. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
13. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
[TBL] [Abstract][Full Text] [Related]
14. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
Menon AA; Sahay S; Braverman LE; Farber HW
Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
Kimmig LM; Liao C; Bag R
Lung; 2020 Feb; 198(1):53-58. PubMed ID: 31912412
[TBL] [Abstract][Full Text] [Related]
19. Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
Airhart S; Verlinden N; Badie N; Raina A; Benza R
J Heart Lung Transplant; 2019 Feb; 38(2):227-230. PubMed ID: 30691597
[No Abstract] [Full Text] [Related]
20. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
